No Detail Found!

Clinical study on the treatment of leukopenia after chemotherapy with leucogen tablets and Shengbai mixture

Author(s)
Yuxiao Zeng Department of Hematology, Lishui People's Hospital (The First Affiliated Hospital of Lishui University),Lishui,China
Jian Li Department of Gastroenterology, Longquan City People's Hospital,Longquan,China
Tao Lian Department of Gastroenterology, Longquan City Hospital of Traditional Chinese Medicine,Longquan,China
Yongwei Zhuang Department of Gastroenterology, Lishui People's Hospital (The First Affiliated Hospital of Lishui University), Lishui, China;Xinjiang Medical University, Urumqi, China
Abstract
This prospective study evaluated the efficacy and safety of Paksun Combination in combination with lisdexamfetamine versus lisdexamfetamine monotherapy for the treatment of chemotherapy-induced leukopenia. A 12month randomized controlled trial (January to December 2022) assigned 96 patients with leukopenia to two treatment groups by computer-generated block randomization. The intervention group (48 patients) received lisdexamfetamine (20 mg, TID) plus leucovorin (20 mL, TID), while the control group (48 patients) received lisdexamfetamine only. The primary outcomes included hematologic recovery parameters, TCM symptom improvement and immunologic indices. The combination therapy demonstrated significantly higher clinical response rates (93.75% vs 75.00%; ?²=15.507, P<0.001), with accelerated leukocyte recovery (5.46±0.41 vs 4.07±0.50×109/L; P<0.001) and neutrophil restoration (2.78±0.69 vs 2.17±0.73×109/L; P=0.025). Immunological improvements included increased IgG (20.81±2.77 vs 17.95±3.10 g/L; P<0.001) and IgM levels (1.59±0.30 vs 1.07±0.24 g/L; P<0.001). No significant difference in adverse events was observed between groups (10.42% vs 18.75%; P=0.247). The combination of Shengbai mixture and leucogen demonstrates significantly enhanced myeloprotective efficacy with safety profiles comparable to those of leucogen monotherapy, thereby underscoring its potential as a highly effective therapeutic modality.
Publication Details
Page(s) 2025-2030
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 6, Year: 2025

Request the full text from PASTIC

Keywords
Leukopenia, chemotherapy, Immunoglobulin, adverse reactions, Shengbai mixture
References
Ahn L,Park SW,Choi DJ SW .2024 .Bojungikgi-tang for chemotherapy-induced leukopenia: A systematic review and meta-analysis. Integr. Cancer Ther, 23 : 1563541251.
Baradaran H,Hashem ZA,Dashti-Khavidaki S,Laki B .2022 .Management of drug-induced neutropenia, thrombocytopenia and anaemia after solid organ transplantation: A comprehensive review. J. Clin. Pharm, 47(12) : 1895-1912.
Blayney DW,Schwartzberg L DW .2022 .Chemotherapyinduced neutropenia and emerging agents for prevention and treatment: A review. Cancer Treat. Rev., 109 : 102427.
Cao Y,Zhang S,Tang L,Chen Y,Jiang S,Liu L,Gao X .2023 .Exploring the effects of Qijiao Shengbai capsule on leukopenic mice from the perspective of intestinbased on metabolomics and 16S rRNA sequencing. Heliyon, 9(9) : e19949.
Li R,Zhang T,Yan SH,Yan YZ,Ding YC,Wang YS,Yang YF .2024 .Chinese medicine combined with adjuvant chemotherapy for improving myelosuppression in colorectal cancer patients: A systematic review and network meta-analysis. Chin J. Integr Med, 30(7) : 643-652.
Li Y,Xiong C,Qin E,Yu Z,Li L,Zhuang G .2018 .Effectiveness of traditional Chinese medicine on chemo-radiotherapy induced leukaemia in patients with lung cancer: A meta-analysis. J. Tradit. Chin. Med, 38(5) : 661-667.
Ma LX,Ai P,Li H,Vardy J .2015 .The prophylactic use of Chinese herbal medicine for chemotherapyinduced leucopenia in oncology patients: A systematic review and meta-analysis of randomized clinical trials. Support. Care Cancer, 23(2) : 561-579.
Wang H,Li Y,Lu J,Qiu M,Cheng D,Zhang X,Yuan W .2021 .Shengbai decoction enhances the anti-tumor efficacy of cyclophosphamide on hepatoma 22-bearing mice. Biomed, 140 : 111775.
Wang H,Qiu M,Li Y,Cheng D,Yang D,Yuan W .2020 .Combination of cyclophosphamide and shengbai decoction has synergistic effect against melanoma. Biomed, 126 : 109866.
Wang KH,Shen HS,Chu SC,Wang TF,Lin CW,Huang WH,Wu YF,Ho CC,Pang CY,Li CC .2024 .Effectiveness of Chinese herbal medicine as a complementary treatment for neutropenia prevention and immunity modulation during chemotherapy in patients with breast cancer: Protocol for a real-world pragmatic clinical trial. JMIR. Res. Protoc., 13 : e55662.
Wang Q,Xu X,Zhang K,Zhang SL,Liu L,Wu Q,Tu PF,Song YL,Zhao YF,Li J .2022 .[Chemome profiling of Qijiao Shengbai Capsules by UPLC-IT-TOF-MS]. Zhongguo Zhong Yao Za Zhi, 47(18) : 4938-4949.
Wang Q,Ye H,Wang QQ,Li WT,Yu BB,Bai YM,Xu GH .2021 .Chinese herbal medicine for chemotherapy-induced leukopenia: A systematic review and meta-analysis of high-quality randomized controlled trials. Front Pharmacol, 12 : 573500.
Yang S,Che H,Xiao L,Zhao B,Liu S B .2021 .Traditional Chinese medicine on treating myelosuppression after chemotherapy: A protocol for systematic review and meta-analysis. Medicine, 100(4) : e24307.
Yao L,Feng W,Tao Y,Tang C Y .2022 .Effect of Shengbai decoction on chemotherapy-induced myelosuppression and survival of gastric cancer patients after radical resection: A retrospective study. Med. Sci. Monitor, 28 : e935936.
Zhang HW,Lin ZX,Cheung F,Cho WC,Tang JL WC .2018 .Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer. Cochrane Db. Syst. Rev., 11(11) : CD010559.
Zhang M,Wang Q,Li X,Zhao W,Hu K,Huang Q,Song Y,Shao R Y .2023 .Integrated strategy facilitates rapid in-depth chemome characterization of traditional Chinese medicine prescriptions: Shengbai oral liquid as a case. J. Sep. Sci., 46(19) : e2300350.
0

Citations

0

Downloads

108

Views